Please login to the form below

Not currently logged in
Email:
Password:

UCB extends agreement with Novartis

UCB Germany has made an agreement with Novartis to extend commercial rights in Germany for the cardiovascular medication Provas beyond 2011

UCB Germany, an affiliate of the Belgian biopharmaceutical company, has made an agreement with Novartis to extend commercial rights in Germany for the cardiovascular medication Provas (valsartan) beyond 2011. 

The company has also negotiated rights for the hypertension treatments Dafiro (valsartan and amlodipine) and Dafiro HCT (valsartan, amlodipine and HCT) and will also co-market  two new oral diabeties therapies Jalra (vildagliptin Icandra and vildagliptin + metformin).

Willy Cnops, vice president  of UCB and managing director of the German operation, said in a  statement: "We are extending our cardiovascular and metabolic product portfolio with the most attractive and innovative treatment options to date in line with UCB's ambitions to offer the best medicines to our patients."

25th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi’s philosophy is to go that extra mile. Look deeper. Discuss further.Study longer. Work harder.This focussed work ethic combined...

Latest intelligence

Emma Walmsley 2
30 women leaders in UK healthcare (part 3)
Part 3 of our list of thirty women leaders...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...
Ingrid
30 Women Leaders in UK Healthcare (part 2)
Part two of our list of thirty women leaders 11-20...

Infographics